Novo Nordisk on next potential weight-loss drug: We are constantly working to improve our supply
Novo’s weight-loss drug Wegovy has been affected by sales restrictions due to high demand. Efforts are now being made to improve the supplies of the next candidate, says the executive vice president.
The work to secure sufficient supplies of Novo Nordisk’s next potential obesity drug is already in full swing, says executive vice president Camilla Sylvest in an interview with MedWatch, conducted during the company’s quiet period leading up to the quarterly report on May 2.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
